Original Article

Economic Burden of Multiple Sclerosis Drugs in Iran during 2011-2019

Abstract

Background: Due to the invariably progressive nature of multiple sclerosis (MS) and the high economic burden of chronic diseases, this study was performed to estimate the economic burden of MS medications in Iran.

Methods: The present research is a descriptive study performed using comprehensive national data of Iran’s Health Insurance Organization (IHIO). The timeframe for study was 2011-2019. In order to calculate the economic burden of MS medications, the cost of illness (COI) method based on the prevalence approach was used. In this study, economic burden estimation was performed according to available data on medication costs. Data mining was also used to perform different stages of study.

Results: The number of patients receiving MS medications covered by IHIO has increased from 19,367 in 2011 to 50,642 in 2019. The economic burden of MS medications of patients covered by the IHIO increased from $81 million to $96 million between 2011 and 2019, respectively. Among the 9 medications studied, Interferon accounted for a very high share of costs in all years. The cost per patient receiving medication has also increased from $7,000 in 2011 to $18,000 in 2019.

Conclusion: Calculations of the economic burden of MS medications in Iran showed an upward trend during the 9 years of the study, which due to the increasing number of patients in Iran, the arrival of new medications and also the increase in prices.

1. Paz-Zulueta M, Parás-Bravo P, Cantarero-Prieto D, Blázquez-Fernández C, Oterino-Durán A (2020). A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord , 43:102162.
2. Imani A GM, Omrani A,Alikhani M, Delpasand M , Vafaee R, Mozafari AA, (2013). Analysis of Thraputic Expenditure in Patients with Multiple Sclerosis in Iran. Scientific Journal of Ilam University of Medical Sciences, 21:169-177.
3. Hartung DM (2017). Economics and cost-effectiveness of multiple sclerosis therapies in the USA. Neurotherapeutics, 14:1018-1026.
4. Dehestani Ardakani M (2020). Effect of Aerobic Exercise Program on Quality of Life in Male Patients with Multiple Sclerosis. SSU_Journals, 28:2971-2981.
5. Chen AY, Chonghasawat AO, Leadholm KL (2017). Multiple sclerosis: frequency, cost, and economic burden in the United States. J Clin Neurosci, 45:180-186.
6. Ponzio M, Gerzeli S, Brichetto G, Bezzini D, Mancardi GL, Zaratin P, Battaglia MA (2015). Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. Neurol Sci, 36:227-234.
7. Imani A, Gharibi F, Khezri A, Joudyian N, Dalal K (2020). Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran. BMC Neurol, 20:1-10.
8. Ghandehari K, Riasi HR, Nourian A, Boroumand AR (2010). Prevalence of multiple sclerosis in north east of Iran. Mult Scler, 16:1525-6.
9. Maghzi A, Ghazavi H, Ahsan M, Etemadifar M, Mousavi S, Khorvash F, Minagar A (2010). Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study. Mult Scler, 16:359-361.
10. Saadatnia M, Etemadifar M, Maghzi AH (2007). Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol, 79:357-375.
11. Lorefice L, Fenu G, Frau J, Coghe G, Marrosu MG, Cocco E (2018). The burden of multiple sclerosis and patients’ coping strategies. BMJ Supportive & Palliative Care, 8:38-40.
12. Naci H, Fleurence R, Birt J, Duhig A (2010). Economic burden of multiple sclerosis. Pharmacoeconomics, 28:363-379.
13. Svendsen B, Grytten N, Bø L, Aarseth H, Smedal T, Myhr K-M (2018). The economic impact of multiple sclerosis to the patients and their families in Norway. Eur J Health Econ, 19:1243-1257.
14. Bruno D, Marc D, Ouarda P, et al (2019). Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. Mult Scler Relat Disor, 36:101396.
15. Ghanati E, Hadiyan M, Asli AD (2011). Economic expenditures of multiple sclerosis medications and feasibility of providing health insurance policies for medications. Journal of Health Administration (JHA), 14.
16. Owens GM (2016). Economic burden of multiple sclerosis and the role of managed care organizations in multiple sclerosis management. Am J Manag Care, 22:s151-s158.
17. Costa N, Derumeaux H, Rapp T, et al (2012). Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev 2:1-12.
18. Ahmad H, Campbell JA, van der Mei I, Taylor BV, Zhao T, Palmer AJ (2020). The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs. Mult Scler Relat Disor, 44:102247.
19. Alowayesh MS, Ahmed SF, Al-Hashel J, Alroughani R (2019). Economic burden of multiple sclerosis on Kuwait health care system. PLoS One, 14:e0216646.
20. Nikseresht A, Izadi S, Rahimi JA (2012). Usage and costs of treatment with beta interferon among patients with multiple sclerosis in Fars province. Hakim Health Systems Research Journal, 14(3): 159.
21. Nana A, Ruth AM, Christina B, et al (2017). Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. Health Promot Chronic Dis Prev Can, 37(2):37-48.
Files
IssueVol 52 No 2 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v52i2.11894
Keywords
Multiple sclerosis (MS) Economic burden Medication costs Iran
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Asadollahi M, Darvishi A, Azimi A, Annabi M, Jafariazar Z, Heshmat R. Economic Burden of Multiple Sclerosis Drugs in Iran during 2011-2019. Iran J Public Health. 2023;52(2):407-419.